Transforming growth factor-beta receptor type I (TGFBR1) (TGFBR1)

Transforming growth factor-beta receptor type I (TGFBR1), also known as ALK5, is a transmembrane serine/threonine kinase that serves as a critical component of the TGF-beta signaling pathway (UniProt: P36897). Upon the binding of TGF-beta ligands to the type II receptor (TGFBR2), TGFBR1 is recruited into a heteromeric complex where it is phosphorylated and activated by TGFBR2. Once active, TGFBR1 phosphorylates intracellular SMAD2 and SMAD3 proteins, which then form complexes with SMAD4 and translocate to the nucleus to regulate the transcription of genes involved in cell proliferation, differentiation, and extracellular matrix production (NCBI Gene: 7046). In the context of disease, TGFBR1 signaling is frequently implicated in the progression of various cancers by promoting epithelial-mesenchymal transition (EMT), metastasis, and creating an immunosuppressive tumor microenvironment (PubMed: 24631412). It also plays a pivotal role in fibrotic diseases, such as pulmonary and renal fibrosis, by driving the overproduction of collagen. Therapeutic strategies targeting TGFBR1 primarily involve small molecule kinase inhibitors, like Galunisertib, which aim to block these pathological processes, though clinical use is carefully managed due to potential side effects like cardiotoxicity and skin lesions (PubMed: 28245158).

Other names

ALK5Activin receptor-like kinase 5SKR3ACVRLK4TGF-beta receptor type IAAT5

ATP-competitive inhibition of the intracellular serine/threonine kinase domain of TGFBR1, which prevents the phosphorylation of SMAD2 and SMAD3, thereby blocking the canonical TGF-beta signaling pathway and its downstream transcriptional effects (PubMed: 24631412).